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Since its discovery as an adipocyte-secreted hormone, leptin has been found to impact food intake, energy
homeostasis, and metabolism through its effects on the central nervous system and peripheral organs.
Recent research indicates that leptin may also be involved in cognition, immune function, and bone meta-
bolism. These findings place leptin at the intersection of neuroendocrinology and metabolism, and possibly
immune function, and render it an appealing therapeutic target for several niche areas of unmet clinical need.
Current evidence regarding classic and emerging roles of leptin as well as the pros and cons of its potential
clinical use are summarized herein.Introduction
As a weight loss drug, leptin has proven to be efficacious in
patients with congenital and acquired leptin deficiency (Chan
et al., 2006; Farooqi et al., 2002; Licinio et al., 2004) but not in
most obese humans, who are found to be resistant to the effects
of leptin (Heymsfield et al., 1999). Leptin plays an important role
in maintaining energy homeostasis in energy-deficient states,
which include acute fasting, exercise- or diet-induced hypotha-
lamic amenorrhea, and also improves metabolism in lipodystro-
phy, all of which are associated with relative hypoleptinemia
(Kelesidis et al., 2010). In these leptin-sensitive states, leptin
regulates food intake, energy expenditure, neuroendocrine
function, metabolism, bone metabolism, and immune function.
Given the evolution in our understanding of leptin physiology,
the leptin field has shifted its focus from leptin’s role as an
antiobesity hormone to its role in weight loss maintenance.
Importantly, the mechanisms underlying leptin resistance in
obesity still remain to be elucidated. Here, we offer a description
of leptin physiology; an overview of its multiple roles, focusing on
its role in energy homeostasis and neuroendocrine regulation;
and insights into its emerging role in the neurobiology of eating
behavior.
Leptin Biology
Leptin is a 167-amino-acid peptide that is primarily produced in
adipose tissue. Circulating leptin levels are directly proportional
to the amount of body fat and fluctuate with acute changes in
caloric intake (Chan et al., 2003), thereby signaling the amount
of stored energy. This is evidenced by our initial study of six
healthy, lean men, in whom 3 days of fasting resulted in leptin
levels falling to 10% of baseline (Chan et al., 2003). Women
tend to have higher leptin levels than men even after correction
for differences in body fat composition, as subcutaneous fathas been associated with higher levels of leptin messenger
RNA (mRNA) expression compared to visceral fat. However,
leptin levels decline significantly after menopause, and it has
been proposed that estrogen increases leptin levels, while
androgens suppress them (Rosenbaum and Leibel, 1999).
Leptin binds to its receptors located throughout the central
nervous system as well as in several peripheral tissues.
Numerous splice variants have been identified, but the LepRb
isoform is the main receptor isoform responsible for leptin
signaling. It is strongly expressed throughout the central nervous
system, particularly in the hypothalamus, where it regulates
energy homeostasis and neuroendocrine function (Kelesidis
et al., 2010). Binding to LepRb activates a number of signaling
pathways (Figure 1) that facilitate leptin’s central and peripheral
effects. These include the janus kinase 2 (JAK2)/signal trans-
ducer and activator of transcription 3 (STAT3), src homology-
2-containing protein tyrosine phosphatase 2 (SHP2)/mitogen-
activated protein kinase (MAPK), phosphatidylinositol 3 kinase
(PI3K)/v-Akt murine thymoma viral oncogene homolog (Akt)/
mammalian target of rapamycin (mTOR), forkhead box protein
O1 (FoxO1), and 50 adenosinemonophosphate-activated protein
kinase (AMPK) pathways (Kelesidis et al., 2010) (Table 1).
Disrupted leptin signaling may result in leptin resistance,
which is generally defined as the failure of endogenous or exog-
enous leptin to promote anticipated salutary metabolic out-
comes, such as suppression of appetite and weight gain and
stimulation of energy expenditure. Leptin resistance typically
accompanies states of energy excess, such as garden-variety
obesity, and may result from interference with JAK2 phosphory-
lation by several intracellular signaling molecules, including
suppressor of cytokine signaling 3 (SOCS3), SHP2, and protein
tyrosine phosphatase 1B (PTP1B) (Myers et al., 2010). Other
mechanisms that may contribute to leptin resistance includeCell Metabolism 18, July 2, 2013 ª2013 Elsevier Inc. 29
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Figure 1. Intracellular Leptin Signaling
Pathways
Binding of leptin to the LepRb receptor results in
its dimerization and prompts JAK2 phosphoryla-
tion and activation of the JAK2/STAT3 pathway.
STAT3 phosphorylation causes it to dissociate
from the LepRb receptor and form active dimers,
which regulate gene expression after translocation
to the nucleus. STAT3 signaling may activate
STAT5, which may also regulate STAT3-
dependent gene expression. JAK2 phosphoryla-
tion also activates SHP2, which then recruits the
adaptor protein Grb2 to prompt activation of
ERK1/2. SOCS3 expression is induced by
STAT3 upon LepRb dimerization and acts as
a negative-feedback signaling compound by
inhibiting leptin-stimulated phosphorylation of
JAK2. Leptin-mediated PI3K activation via IRS1/2
causes Akt/mTOR phosphorylation and subse-
quent regulation of S6 and FOXO1 activity. PTP1B
may interfere with PI3K activation by inhibiting
leptin-stimulated IRS-1/2 phosphorylation. Akt,
v-Akt murine thymoma viral oncogene homolog;
ERK1/2, extracellular signal-regulated kinase 1/2; FOXO1, forkhead boxO1; Grb2, growth factor receptor-bound protein-2; IRS, insulin receptor substrate; JAK2,
janus kinase 2; LepRb, leptin receptor; mTOR,mammalian target of rapamycin; PI3K, phosphatidylinositol 3 kinase; PTP1B, protein tyrosine phosphatase 1B; S6,
ribosomal protein 6; SHP2, src homology-2-containing protein tyrosine phosphatase 2; SOCS3: suppressor of cytokine signaling 3; STAT, signal transducer and
activator of transcription.
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ficking from the trans-Golgi network to the cellular membrane,
and obesity-associated endoplasmic reticulum (ER) stress and
chronic low-level inflammation, both of which can impair LepRb
signaling (Moon et al., 2011). It is important to distinguish these
mechanisms from several models of genetic obesity, in which
mutations in or downstream of the LepRb gene block proper
leptin response (Myers et al., 2010). The role in and partial contri-
bution of each mechanism to leptin resistance remain to be fully
elucidated. Table 2 shows disease states associated with leptin
deficiency and leptin resistance.
The Role of Leptin in Regulating Food Intake and Energy
Expenditure
In response to energy deprivation, leptin levels fall before and out
of proportion to loss of fat mass (Boden et al., 1996), initiating
several mechanisms to increase energy intake and conserve
energy expenditure. These adaptations have been noted in
healthy subjects in response to a short-term fast, women with
hypothalamic amenorrhea who are chronically energy deprived,
patients with lipodystrophy, and those with recent weight loss.
The Role of Leptin in Regulating Food Intake
Numerous studies of leptin-deficient individuals have shown that
leptin treatment affects food intake and satiety. In patients with
congenital leptin deficiency, which is well characterized by
hyperphagia and severe, early-onset obesity, treatment with
leptin results in decreased food intake, increased physical activ-
ity, and decreased weight (Farooqi et al., 2002). In subjects with
relative hypoleptinemia due to 10% weight loss, exogenous
leptin replacement blunted the decrease in satiation observed
after weight loss, although it did not change absolute food intake
(Kissileff et al., 2012).
These effects are mainly central. Leptin interacts with several
neuronal pathways in the brain, particularly the hypothalamus, to
regulate food intake via orexigenic and anorexigenic neuropep-
tides (Figure 2). In the arcuate nucleus (ARC) of the hypothala-
mus, leptin activates neurons that express pro-opiomelanocortin30 Cell Metabolism 18, July 2, 2013 ª2013 Elsevier Inc.(POMC) and cocaine- and amphetamine-regulated transcript
(CART), both of which suppress appetite, and inhibits neurons
that express agouti-related peptide (AgRP) and neuropeptide Y
(NPY), both of which stimulate appetite (Cowley et al., 2001).
The effect of leptin on POMC neurons is partly mediated via
GABAergic presynaptic neurons found in the ARC, dorsomedial
hypothalamus, and lateral hypothalamus (LHA); via GABAergic
neurons, leptin reduces inhibitory tone to POMC neurons
(Vong et al., 2011), thereby enhancing their antiorexigenic action.
In the LHA, leptin also decreases the expression of the orexi-
genic neuropeptides melanin-concentrating hormone (MCH)
(Bayer et al., 1999) and orexin (Yamanaka et al., 2003). In the
ventromedial hypothalamus (VMH), leptin acts on neurons that
express steroidogenic factor-1 (SF-1) (Kim et al., 2011), through
which it possibly induces thermogenesis after acute exposure to
high-fat diet, and brain-derived neurotrophic factor (BNDF) (Liao
et al., 2012), through which it inhibits food intake.
LepRb-expressing neurons have also been found in the
nucleus of the solitary tract (NTS) of the hindbrain and include
subpopulations that express POMC, proglucagon/glucagon-
like peptide 1 (GLP-1), and cholecystokinin (CKK) (Garfield
et al., 2012). Leptin may also act synergistically with gastrointes-
tinal hormones in this region to promote satiety, and leptin
administration to mice has been found to enhance the anorexic
and weight loss responses to intraperitoneally administered
CCK, GLP-1, and amylin (Figure 2).
Leptin also influences the hedonic aspects of feeding via inter-
actions with the mesolimbic dopaminergic system, which is
known to regulate reward, mood, and arousal (Dardeno et al.,
2010) (Figure 2). In rats, direct administration of leptin into the
ventral tegmental area (VTA) reduces the excitability of dopa-
mine neurons in the area and decreases food intake, while
knockdown of LepRb in the VTA increases food intake and
preference for highly palatable food (Hommel et al., 2006). In
addition, leptin administration directly into the LHA promotes
expression of tyrosine hydroxylase, a rate-limiting enzyme
involved in the production of dopamine, in the VTA (Leinninger
Table 1. Leptin-Activated Signaling Pathways
Signaling Pathway Effects of Pathway Activation Evidence
JAK2/STAT3: tyrosine kinase signaling
pathway responsible for leptin signal
transduction
CNS regulation of adipose tissue
maintenance
Neural disruption of the STAT3 pathway results in severe
obesity in mice
Stimulation of anorectic pathways
in ARC of hypothalamus
[POMC transcription; YAgRP/NPYa transcription
SHP2/MAPK: upstream activator of the
MAPK pathway
CNS regulation of energy homeostasis ERK1/2 activation by JAK2; ERK1/2 is the primary
MAPK implicated in leptin’s central regulation of energy
homeostasis
PI3K/Akt/mTOR: kinase pathway that
mediates leptin’s effects on insulin
metabolism and cellular proliferation
Activation of growth pathways/cellular
proliferation pathways
Akt activation corresponds with cellular proliferation in
several murine peripheral tissue cell lines
Anorectic central effects Initiation of the PI3K pathway activates POMC-expressing
neurons
Mediation of leptin’s impacts on insulin
metabolism
The PI3K/Akt/mTOR pathwaymay play a role in pancreatic
islet function
FoxO1: orexigenic downstream
mediator of the PI3K pathway
Orexigenic central effects FoxO1 activation the expression of POMC and promotes
the expression of AgRP and NPY in the CNS; leptin
administration inhibits FoxO1 activity and expression in a
PI3K-dependent manner
Point of intersection for leptin and insulin
signaling
Deletion of IRS2 in LepRb CNS neurons deregulates PI3K
signaling and results in increased FoxO1 signaling
AMPK: serine/threonine protein kinase
that modulates energy regulation
Peripheral adipose tissue maintenance Peripherally promotes increased fatty-acid oxidation and
various insulin-sensitizing effects
Orexigenic central effects In the CNS promotes increased food intake and weight
gain; leptin inhibits AMPK centrally and activates it
peripherally
SOCS3: key negative feedback molecule
in leptin signaling
Possibly mediates leptin resistance in
obesity
Interferes with JAK2/STAT3 activation SOCS3 mRNA is
increased in leptin-resistant mouse model of obesity
SHP2: Src homology-2-containing
tyrosine phosphatase implicated in
growth-factor and cytokine signaling
May be a therapeutic target for treatment
of leptin resistance; possibly mediates
leptin resistance in obesity
SHP2’s interference in JAK2/STAT3 activation is
counteracted by the SHP2-mediated upregulation of the
leptin-ERK1/2 pathway
PTP1B: negative regulator of leptin-
stimulated pathways
Possibly mediates leptin resistance in
obesity
PTP1B binds to and dephosphorylates JAK2
AgRP, agouti-related peptide; Akt, v-Akt murine thymoma viral oncogene homolog; AMPK 50, adenosine monophosphate-activated protein kinase;
ARC, arcuate nucleus; CNS, central nervous system; ERK, extracellular-signal-regulated kinase; FoxO1, forkhead box protein O1; IRS, insulin receptor
substrate; JAK, janus kinase; LepR, leptin receptor; MAPK, mitogen-activated protein kinase; mTOR, mammalian target of rapamycin; NPY, neuro-
peptide Y; PI3K, phosphatidylinositol 3 kinase; POMC, pro-opiomelanocortin; PTP1B, protein tyrosine phosphatase 1B; SHP, src homology-2-
containing protein tyrosine phosphatase; SOCS, suppressor of cytokine signaling; STAT, signal transducer and activator of transcription.
aThe orexigenic NPY system may also be regulated through STAT3-independent LepRb signals.
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creases both the incentive to feed and pleasure from eating
through influencing the mesolimbic dopamine system.
The Role of Leptin in Regulating Energy Expenditure
In addition to controlling energy intake via central regulation of
appetite and satiety, leptin also regulates energy expenditure
via the central nervous system, possibly through the suppression
of MCH and FoxO1. Compared to ob/ob mice, which are leptin
deficient, double-null mice to ob/ob and MCH-1 receptor have
increased locomotor activity, increased resting energy expendi-
ture, and dramatically less body fat, despite similar food intake
(Segal-Lieberman et al., 2003). Mice with FoxO1 deletion in
SF-1 neurons of the VMH had higher energy expenditure during
fasting, likely through activation of the sympathetic nervous sys-
tem (Kim et al., 2012). Finally, administration of leptin has been
shown to increase sympathetic outflow to brown adipose tissue,
which may mediate increased expression of uncoupling protein
in rodents (Scarpace et al., 1997).Similar findings have beenmore difficult to confirm in humans.
In two children with congenital leptin deficiency, leptin adminis-
tration did not have a major effect on basal metabolic rate or
total energy expenditure (Farooqi et al., 2002). Interestingly, in
adults with congenital leptin deficiency, leptin replacement
prevented the fall in energy expenditure observed after weight
loss (Galgani et al., 2010). In our experience with healthy,
normal-weight women, leptin replacement did not prevent the
decrease in catecholamine levels, the increase in heart rate, or
the decrease in cardiac vagal modulation observed after a
short-term fast (Chan et al., 2007). On the other hand, in sub-
jects on a longer-term weight loss program, leptin replacement
has been shown to reverse in part the decrease in energy
expenditure in addition to the changes in skeletal muscle work
efficiency and sympathetic nervous system tone associated
with weight loss (Kissileff et al., 2012; Rosenbaum et al.,
2005), but these data need to be confirmed by studies by other,
independent groups.Cell Metabolism 18, July 2, 2013 ª2013 Elsevier Inc. 31
Table 2. Disease States Associated with Leptin Deficiency and Leptin Resistance
Disease States Estimated Prevalence Clinical Features
Fat Loss Associated with Leptin Deficiency
Congenital generalized
lipoatrophy
Rare Generalized fat wasting, insulin resistance, impaired
glucose tolerance, type 2 diabetes mellitus, dyslipidemia,
hepatic steatosis, acanthosis nigricans
HAART-induced lipoatrophy 15%–36% of HIV-infected patients Fat wasting of the face, arms, legs and buttocks, insulin
resistance, impaired glucose tolerance, type 2 diabetes
mellitus, hypertriglyceridemia, hepatic steatosis
Hypothalamic amenorrhea
(functional)
3%–7.6% in women aged 13–44 years;
up to 69% of trained female athletes
Strenuous exercise, psychogenic stress, energy deficit,
low bone mass and increased bone loss, neuroendocrine
dysfunction with decreased GnRH pulsatility and estradiol
levels, decreased thyroid and IGF-1 levels, increased
growth hormone levels
Anorexia nervosa 1.2%–2.2% lifetime prevalence for women Weight loss to body weight <85% of expected, refusal to
maintain normal body weight, fear of gaining weight,
disturbed body image, severe restriction of food intake,
amenorrhea and other neuroendocrine dysfunction
Obesity as a Manifestation of Leptin Deficiency
Complete congenital leptin
deficiency
Rare Hyperphagia, early-onset morbid obesity, hypogonadotrophic
hypogonadism, hyperinsulinemia and type 2 diabetes
mellitus, dyslipidemia, immune dysfunction
Heterozygous leptin deficiency %6% in obese subjects Garden-variety obesity with hypoleptinemia relative to fat
mass, normal neuroendocrine function
Obesity Associated with Leptin Resistance (Involving Leptin and Molecular Signaling Pathways Downstream of the Leptin Receptor)
Leptin receptor gene mutations Rare Phenotype similar to congenital leptin deficiency,
hyperphagia, less-remarkable hyperinsulinemia,
hypogonadotrophic hypogonadism, abnormal growth
hormone secretion with mild growth delay, hypothalamic
hypothyroidism, immune dysfunction
POMC mutations Rare Hyperphagia, early-onset obesity, ACTH deficiency with
adrenal insufficiency/crisis, lack of MSH function at MC1Rs
resulting in pale skin and red hair
Prohormone convertase 1
deficiency
Rare Hyperphagia, early-onset obesity, hypogonadotrophic
hypogonadism, abnormal glucose homeostasis,
hypoinsulinemia, hypocortisolemia
Melanocortin 4 receptor
mutations
5%–8% of childhood obesity Hyperphagia, early-onset obesity, increased fat and lean body
mass, increased linear growth and bone density, severe
hyperinsulinemia
Melanin-concentrating
hormone receptor-1 mutations
(loss of function)
Rare Markedly underweight individuals
Neurotropin receptor tropomyosin-
related kinase B mutations
Rare BDNF deficiency resulting in hyperphagia, severe obesity,
developmental delay, cognitive dysfunction
Mutations of other molecules
downstream of leptin receptor
Rare Obesity with onset in childhood
Mechanism to be discovered >90% of obese individuals Garden-variety obesity
The table was adapted from the following references: Blu¨her and Mantzoros (2009), Brennan and Mantzoros (2006), Dardeno et al. (2010), and Smink
et al. (2012). ACTH, adrenocorticotropic hormone; BDNF, brain-derived neurotrophic factor; GnRH, gonadotropin-releasing hormone; HAART, highly
active antiretroviral therapy; IGF, insulin-like growth factor; MC1R, melanocortin 1 receptor; MSH, melanocyte-stimulating hormone; POMC, pro-
opiomelanocortin.
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Functional magnetic resonance imaging (fMRI) examines
local neuronal activity as an indirect marker of blood oxygen
supply in the brain from blood-oxygen-level dependent
(BOLD) changes in the paramagnetic properties of hemo-
globin (Carnell et al., 2012). fMRI studies are commonly used32 Cell Metabolism 18, July 2, 2013 ª2013 Elsevier Inc.to evaluate the brain’s response to food imagery or to dif-
ferent categories of food cues. Structural MRI and subsequent
voxel-based morphometry (VBM) analysis may be used to
obtain anatomical details, based upon the different paramag-
netic properties of brain tissues comprising white and gray
matter.
Figure 2. The Effects of Leptin in the Brain
during States of Energy Excess and Energy
Deficiency
During states of leptin and energy excess, leptin
action in the hypothalamus and other brain areas is
impaired and its effects are blunted. In states of
leptin and energy deficiency, leptin is effective;
neuropeptides and brain centers that are normally
activated by leptin are elevated (+) and neuro-
peptides and brain centers inhibited by leptin are
suppressed (–), leading to alterations in neuroen-
docrine function and energy homeostasis. As
highlighted in studies using neuroimaging, alter-
ations in leptin levels also affect feeding behavior
via activation or inactivation of certain brain
centers. The figure has been adapted from the
following references: Blu¨her and Mantzoros
(2009), Brennan and Mantzoros (2006), Chan and
Mantzoros (2005), and Dardeno et al. (2010).
ACTH, adrenocorticotropic hormone; AgRP,
agouti-related peptide; ARC, arcuate nucleus;
BDNF, brain-derived neurotrophic factor; CART,
cocaine- and amphetamine-regulated transcript;
CCK, cholecystokinin; CRH, corticotropin-
releasing hormone; FSH, follicle-stimulating hor-
mone; GH, growth hormone; GLP-1, glucagon-like peptide 1; GnRH, gonadotropin-releasing hormone; IGF-1, insulin-like growth factor 1; LH, luteinizing
hormone; LHA, lateral hypothalamic area; MCH,melanin-concentrating hormone; NPY, neuropeptide Y; NST, nucleus of the solitary tract; PFC, prefrontal cortex;
PO, preoptic area; POMC, proopiomelanocortin; PVN, paraventricular nucleus; SF-1, steroidogenic factor-1; SN, substantia nigra; TRH, thyrotropin-releasing
hormone; TSH, thyrotropin-stimulating hormone; VMH, ventromedial hypothalamus; VS, ventral striatum; VTA, ventral tegmental area.
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sogenic phenotype’’ of brain activity, which is generally charac-
terized by (1) hyperactivity in a food-related network of brain
areas involved in reward (e.g., striatum, insula, orbitofrontal
cortex [OFC]), motor/sensor processing (e.g., insula, precentral
gyrus) and emotion/memory (e.g., amygdala, hippocampus)
and (2) hypoactivity in brain regions associated with homeostatic
control (e.g., hypothalamus) and attention/cognitive control
(e.g., prefrontal cortex [PFC], cingulate gyrus) (Carnell et al.,
2012). The obesogenic phenotype is influenced by emotion,
cognition, and behavior, as well as by genetic and environmental
parameters.
Given that leptin may regulate hedonic response to food via
the mesolimbic system, neuroimaging studies have attempted
to illuminate leptin’s role in homeostatic regulation of feeding in
the context of (1) congenital or acquired leptin deficiency and
(2) leptin resistance states.
Neuroimaging Studies in Patients with Congenital Leptin Defi-
ciency. Three neuroimaging studies have investigated the
functional effects of leptin treatment on the brain in congenitally
leptin-deficient patients using fMRI (Baicy et al., 2007; Farooqi
et al., 2007; Frank et al., 2011), and three other studies conduct-
ed in individuals with congenital leptin deficiency have investi-
gated the structural effects associated with leptin deficiency
and replacement using MRI/VBM to assess increased gray
matter tissue concentration (London et al., 2011; Matochik
et al., 2005; Paz-Filho et al., 2008b); these data are summarized
in Table 3. In brief, based on these fMRI studies, leptin seems to
increase satiety, direct homeostatic- and reward-related brain
areas toward lower intake and selection of low-caloric food
through interactions with cortical regions (Table 3). Based on
MRI/VBM studies, leptin may regulate brain plasticity—and
thereby play a role in normal brain development in children—
and may increase gray matter in adults in regions regulating
hunger and satiation (Table 3). The major limitation of all thesestudies is their very small sample size; however, due to disease
rarity, it is rather difficult to perform clinical trials with large
sample sizes in patients with congenital leptin deficiency. A
better understanding of leptin’s effects on neurogenesis, axon
growth, synaptogenesis, dendritic morphology, neuron excit-
ability, and regulation of b-amyloid levels in both subjects with
leptin deficiency and those with adequate leptin levels may
lead to leptin-based therapies for not only congenital leptin defi-
ciency, but also mood and neurodegenerative disorders.
Neuroimaging Studies in Leptin-Resistance States. Obesity,
which is probably the most prevalent leptin-resistant state, is
notably associated with numerous alterations to brain activity.
Late-life obesity is associated with smaller global and regional
gray matter volumes (Brooks et al., 2013) and long-term obesity
has been associated with cerebral atrophy (Matochik et al.,
2005). Obese, in comparison to lean, individuals have reduced
gray matter in several brain areas, including regions involved in
the regulation of taste (i.e., inferior frontal operculum and post-
central gyrus), reward (i.e., putamen) and behavioral processing
(i.e., middle frontal gyrus) (Pannacciulli et al., 2006). Other
changes seen in obese individuals include enlarged volumes in
the orbitofrontal white matter (Pannacciulli et al., 2006) and
neuronal and myelin abnormalities in the frontal lobes (Gazdzin-
ski et al., 2008). These abnormalities may be the consequence of
several underlying parameters/comorbidities, such as subclini-
cal inflammation, reduced physical activity, impaired respiratory
function, hypercortisolemia, hypertension, hyperlipidemia, car-
diovascular disease, type 2 diabetes mellitus, and impaired lep-
tin signaling and function manifested in garden-variety obesity.
Notably, a VBM-based study showed an independently nega-
tive association between fasting plasma leptin concentrations,
which are increased in garden-variety obesity, and the volume
of gray matter in brain areas in which obese people typically
exhibit reduced gray matter compared to their lean counterparts
(Pannacciulli et al., 2007); although this cannot directly prove aCell Metabolism 18, July 2, 2013 ª2013 Elsevier Inc. 33
Table 3. Summary of Neuroimaging Studies in Patients with Congenital Leptin Deficiency
Referencea Main Findings Main Highlights
fMRI Studies
Farooqi et al. (2007):
two patients, 7 days
(1) The anteromedial and posterolateral ventral
striatum were markedly activated in response to food
pictures in the baseline leptin-deficient state
compared to the leptin-replaced state; (2) leptin
reduced food intake, decreased hunger in the fasting
state, increased postprandial satiety, and decreased
liking of food pictures in the fed state
Leptin via the mesolimbic system (striatal regions)
reduces the perception of food reward while
enhancing the response to satiety signals produced
during food consumption
Baicy et al. (2007):
three patients, 57 months
followed by 1 month of
discontinuation and 14 days
of reinstitution
(1) Leptin reduced activation in brain regions linked to
hunger, including the insular cortex and parietal and
temporal cortex; (2) leptin increased activation in brain
regions linked to satiety, including the PFC (middle,
superior, and medial frontal gyri) in response to
high-caloric pictures
The greater activation of the PFC in the leptin-replaced
state may mediate behavioral inhibition and satiety
control (i.e., inhibition of consuming high-caloric foods)
in accordance with the generally accepted belief that
high-caloric foods are unhealthy and should be
avoided
Frank et al. (2011):
one patient, 6 months
(1) Leptin decreased activation in amygdala (area
responsible for evaluation of emotional salience) and
VTA/substantia nigra, whereas increased activation in
the OFC (area involved in reward and food-related
responses); (2) low- versus high-caloric cues provided
differential effect in VTA and OFC and hypothalamus
(for example, in hypothalamus, activation after low-
caloric cues was gradually increased, whereas
activation after high-caloric cues was gradually
decreased)
Leptin treatment resulted in activity changes in both
homeostatic- and reward-related brain areas, which
generally favored reward system toward a low caloric
diet together with weight loss
MRI/VBM Studies
Matochik et al. (2005):
three patients (with a recessive
mutation in the ob gene),
18 months
Increased gray matter concentration, reflecting an
increase in number or size of neurons, within the
anterior cingulate gyrus, the inferior parietal lobule,
and the cerebellum
Leptin treatment increases number or size of
neurons of brain regions implicated in leptin’s
overhypothalamic neural pathways, regulating hunger
and satiation
Paz-Filho et al. (2008b):
one patient; 2 years
Substantial increase in the rates of development in
most neurocognitive domains, together with some
skills at or exceeding expectations based on
chronological age
Leptin treatment improved neurocognition
London et al. (2011):
three patients, 3 years
(cycle of treatment withdrawal
and reinstitution)
(1) Withholding of leptin treatment increased BMI and
reversed the initial effects of leptin in the cerebellum
and the anterior cingulate gyrus; (2) leptin restoration
did not lead to a short-term recovery of graymatter, but
to an unexpected gray matter increase in the posterior
half of the left thalamus, particularly the pulvinar
nucleus
Leptin treatment may play a therapeutically valuable
role in regulating plasticity-dependent brain functions
BMI, body mass index; fMRI, functional magnetic resonance imaging; MRI, magnetic resonance imaging; OFC, orbitofrontal cortex; PFC, prefrontal
cortex; VBM, voxel-based morphometry; VTA, ventral tegmental area.
aNumber of patients and duration of leptin treatment are indicated.
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reorganization of brain composition in regions recently found
to be associated with excess body fatness.
Leptin supplementation may blunt brain activity in response to
food stimuli in obese adults after weight loss. In an fMRI-based
study, six obese individuals receiving leptin treatment or placebo
(in a crossover fashion), after being stabilized at a weight of
approximately 10% lower of their initial weight, were evaluated.
Leptin administration to these weight-reduced individuals
reversed the increased hunger and decreased satiety that
are characteristic of the weight-reduced state. Moreover, in
response to visual food cues, there were observable leptin-
reversible increases in neural activity of the brainstem, culmen,
parahippocampal gyrus, inferior, and middle frontal gyri, middle34 Cell Metabolism 18, July 2, 2013 ª2013 Elsevier Inc.temporal gyrus, and lingual gyrus and leptin-reversible de-
creases in activity of the hypothalamus, cingulate gyrus, and
middle frontal gyrus (Rosenbaum et al., 2008). Weight loss is
linked to neural activity changes in these brain regions, which
are associated with the emotional, regulatory, and cognitive con-
trol of food intake. Despite the small sample size, the authors
proposed that, after weight loss, which is accompanied by
decreases in leptin due to decreases in stored endogenous
energy, leptin administration decreases the responsiveness to
the emotional and sensory aspects of food and increases the
cognitive control of food intake (Rosenbaum et al., 2008).
Limitations and Future Directions for Neuroimaging Studies.
Overall, current studies provide evidence that leptin treatment
in severe leptin-deficient or leptin-resistant states may alter the
Cell Metabolism
Reviewactivity patters in brain areas related to homeostatic, emotional,
and reward-related processes. It seems that leptin enhances
satiety and cognitive responses to food stimuli, while it dimin-
ishes responses in hedonic, reward-related, and sensory brain
regions. These studies also suggest that leptin may engender
extrahypothalamic effects on human brain tissue composition
and may improve neurocognition. It seems that neuroplasticity
within the human brain partly depends on leptin.
A significant drawback of the above mentioned neuroimaging
studies is their very small sample size, which prohibits general-
ization of the reported results. Moreover, it is difficult to draw
concrete conclusions based on current fMRI studies, as they
have each identified distinct and separate brain regions that
are differentially activated or inhibited by leptin treatment. Meth-
odological discrepancies could explain these observed differ-
ences. For example, the above-discussed fMRI studies differed
with respect to whether they reported results on whole brain or
regions of interest analyses (Baicy et al., 2007; Farooqi et al.,
2007; Frank et al., 2011; Rosenbaum et al., 2008). Other differ-
ences include the control (or lack of control) of dietary intake,
duration of leptin administration, presentation and nature of the
visual stimuli, and the inclusion or exclusion of behavioral tasks
(e.g., hunger ratings) performed by subjects while in the scanner.
Furthermore, congenitally leptin-deficient patients and weight-
reduced subjects may not react similarly to leptin administration
and may exhibit different patterns of brain activation, because of
metabolic, physiological, and developmental difference; such
differences obfuscate our ability to draw a cohesive conclusion
about leptin’s effects on brain activity in states of severe and
partial leptin insufficiency. Moreover, the severity of leptin defi-
ciency (degree and duration) may also have important implica-
tions on the efficacy and/or nature of the brain’s response to
leptin treatment (Paz-Filho et al., 2008b).
Additional neuroimaging studies that examine variable
degrees of leptin deficiency are needed to better understand lep-
tin’s effects on the brain. More studies with a larger sample size,
although difficult to achieve when performing studies for rare
diseases such as congenital leptin deficiency, are also needed
in order to drawmore substantial conclusions about the interplay
between leptin and brain activity. Hopefully, future neuroimaging
studies will reveal the pathways that mediate the interaction
between hedonic/reward and homeostatic/satiety signaling in
states of energy excess, such as obesity (Carnell et al., 2012;
Dardeno et al., 2010; Farooqi et al., 2007).
The Role of Leptin in Regulating Neuroendocrine
Function
Leptin also regulates energy homeostasis by moderating neuro-
endocrine adaptations seen in leptin-deficient states, such as
starvation, hypothalamic amenorrhea, and human immunodefi-
ciency virus (HIV)-associated lipodystrophy, to prevent procre-
ation, slow metabolism, and inhibit growth-related processes
via decreased hypothalamic-gonadal signaling, decreased thy-
roid hormone levels, and decreased insulin-like growth factor-1
(IGF-1) levels (Chan et al., 2003). Patients with congenital leptin
deficiency have several neuroendocrine disorders, including
hypogonadotrophic hypogonadism with failure to reach puberty
(Licinio et al., 2004) and disorganized secretion of thyroid-stimu-
lating hormone (TSH), but not necessarily thyroid dysfunction(Mantzoros et al., 2001). Leptin replacement may permit the
appropriate onset of puberty in individuals with congenital leptin
deficiency (Farooqi et al., 2002; Licinio et al., 2004) and may
increase thyroid hormone levels but does not affect TSH
levels (Farooqi et al., 2002). Unlike mice, children with congenital
leptin deficiency have normal linear growth and adrenal function
(Farooqi et al., 2002).
An acute fall in leptin levels in response to starvation results in
similar neuroendocrine abnormalities. In healthy men, leptin
replacement prevented the fasting-induced fall in testosterone
levels, the changes in LH and TSH pulsatility, and the fall in total
IGF-1 levels, but did not prevent the changes in GH pulsatility,
the decline in free IGF-1 levels, or the increase in 24 hr cortisol
concentration (Chan et al., 2003). In healthy women, leptin
replacement also prevented fasting-induced decreases in LH
pulsatility (Chan et al., 2006). However, administration of leptin
in overweight and obese subjects during weight loss has not
been shown to reverse these changes in thyroid, corticotropic,
and somatotropic axes associated with weight loss, perhaps
because even after weight loss such individuals remain relatively
leptin resistant (Shetty et al., 2011). In contrast, leptin administra-
tion during weight loss maintenance, a time of relative leptin
deficiency, was found to reverse the decreases in both triiodo-
thyronine (T3) and thyroxine (T4) levels but not the decrease in
TSH levels (Rosenbaum et al., 2005), but this study was not
randomized and only of sequential design. This suggests a
potential pleiotropic role for leptin in weight loss maintenance,
especially since leptin levels are found to be significantly
decreased for over a year after weight loss (Sumithran et al.,
2011), but this remains to be shown by well-designed random-
ized clinical trials.
We have shown that leptin replacement has similarly positive
effects on neuroendocrine regulation among women with hypo-
thalamic amenorrhea, who are chronically energy deprived and
have relative hypoleptinemia (Miller et al., 1998). In our proof-
of-concept trial, we showed that leptin treatment in replacement
doses for 12 weeks resulted in increased mean LH levels, LH
pulse frequency, estradiol levels, number of dominant follicles,
free T3 and free T4 levels, and IGF-1 and IGF-binding protein 3
(IGFBP-3) levels; no changes in cortisol or ACTH levels were
found in that initial study, but this might have been due to the
specific study design (Welt et al., 2004). This study was followed
by a randomized, placebo-controlled 36-week trial that con-
firmed increases in the levels of estradiol, progesterone, and
free T3, and in the ratio of IGF1:IGFBP-3 and found a decrease
in cortisol levels with leptin treatment (Chou et al., 2011). These
improvements were independent of any weight gain or decrease
in exercise activity (Chou et al., 2011; Welt et al., 2004). Finally,
70% of subjects on leptin treatment menstruated during the
course of the study compared to 22% of those on placebo
(Chou et al., 2011).
Lipoatrophy is another condition associated with hypoleptine-
mia caused by deficiency or destruction of adipose cells and the
resultant inability to produce leptin (Pardini et al., 1998). In open-
label studies, leptin treatment in female patients with lipodystro-
phy and hypoleptinemia has been shown to restore menses,
increase estradiol levels, decrease testosterone levels, increase
sex hormone binding globulin (SHBG) levels, and normalize LH
response to LH releasing hormone (Musso et al., 2005); fewerCell Metabolism 18, July 2, 2013 ª2013 Elsevier Inc. 35
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et al., 2005). In response to leptin treatment, IGF-1 levels, but
not GH levels, have been found to increase in patients with
generalized or partial lipodystrophy (Musso et al., 2005) but
did not change in patients with highly active antiretroviral-
therapy-induced lipoatrophy with less-profound leptin defi-
ciency (Brennan et al., 2009). No changes were observed in
the hypothalamic-pituitary-adrenal axis (Musso et al., 2005).
These findings indicate that in states of severe hypoleptinemia
leptin may act as a ‘‘master switch’’ for the hypothalamic neuro-
endocrine axes that control metabolism, growth, and reproduc-
tion. Only through increased study of leptin may we come to
harness this physiological feature for therapeutic advantage.
The Role of Leptin in Cognition
Leptin has been associated with beneficial effects on cognition
and memory. Administration of leptin in rabbits reduced accu-
mulation of b-amyloid and phosphorylated tau protein, twomajor
peptides implicated in Alzheimer’s disease, and improved cogni-
tive performance compared to saline-treated littermates (Mar-
warha et al., 2010). Epidemiological studies have reported that
higher leptin levels are prospectively associated with lower
odds of dementia in nonobese persons only (Lieb et al., 2009).
These findings corroborate those from fMRI studies, which
have indicated that plasma leptin levels are positively associated
with total cerebral brain volume (Lieb et al., 2009). This signifies a
therapeutic potential for leptin in the treatment of cognitive
decline and in the optimization of mental function. As the use
of sophisticated neuroimaging techniques further refines our
understanding of leptin’s role in the neurobiology of eating
behavior, this may prove useful in the fields of psychology and
dementia. Additional interventional trials will be necessary to
assess the effects of leptin on mental health and cognition in
the general population or in obese individuals at risk for late-in-
life cognitive decline.
The Role of Leptin in Metabolism
Carbohydrate Metabolism
Leptin administration may improve glucose metabolism in
several leptin-deficient states, including complete leptin defi-
ciency and lipoatrophy, which are associated with insulin resis-
tance and impaired glucosemetabolism. In addition to improving
insulin resistance by decreasing body weight and fat mass,
especially ectopic or intra-abdominal fat (Moran et al., 2004),
leptin can also activate insulin-sensitive tissues. Leptin signaling
in mouse muscle cells has been found to parallel that of insulin
via PI3K activation (Maroni et al., 2005). Similarly, SOCS3, whose
expression is enhanced through the JAK2/STAT3 pathway, acts
as a negative feedback mechanism by attenuating leptin
signaling, which induces leptin resistance; SOCS3 may possibly
also attenuate insulin signaling by inhibiting P13K, thereby simul-
taneously inducing insulin resistance (Polyzos et al., 2011).
Furthermore, in vitro studies have shown that leptin inhibits
insulin gene expression and glucose-stimulated insulin secre-
tion from pancreatic b cells, and in vivo rodent studies have
shown that leptin protects b cells from lipotoxicity (Lee et al.,
2011). These findings suggest that particular mechanisms exist
through which leptin may enhance or modify insulin’s metabolic
effects.36 Cell Metabolism 18, July 2, 2013 ª2013 Elsevier Inc.Patients with congenital leptin deficiency are profoundly
obese and can exhibit insulin resistance with hyperinsulinemia
and diabetes mellitus; leptin replacement has been shown to
improve insulin sensitivity in these individuals (Farooqi et al.,
2002; Licinio et al., 2004). Using mathematical modeling,
Andreev et al. demonstrated that hepatic extraction of insulin
increased 2-fold in a man with congenital leptin deficiency after
1 week of leptin treatment (Andreev et al., 2009). After 24 months
of treatment, insulin sensitivity increased by 10-fold and insulin
secretion decreased by 2-fold, while insulin hepatic extraction
returned to normal (Andreev et al., 2009).
In patients with congenital and acquired lipodystrophies,
including HIV-associated lipodystrophy, leptin treatment results
in significant improvements in glycemia, insulin resistance, and
central obesity, the effects of which appear to be time and
dose dependent (Brennan et al., 2009; Lee et al., 2006; Mulligan
et al., 2009; Musso et al., 2005). In patients with severe, general-
ized lipodystrophy, improvement in glycemic control has been
attributed to a 2-fold increase in insulin suppression of hepatic
glucose production, as well as insulin-stimulated peripheral
glucose disposal (Petersen et al., 2002). These improvements
in hepatic and skeletal muscle sensitivity were associated with
85% reduction in hepatic triglyceride content and 30% reduction
in intramyocellular triglyceride and fatty acyl CoA content
(Petersen et al., 2002).
These improvements in glycemia and insulin resistance have
prompted further research into leptin’s role in diabetes mellitus.
Studies in lipoatrophic mice showed that leptin monotherapy at
pharmacological doses normalizes glucose levels and improves
glucose variability, a finding attributable to leptin’s ability to sup-
press glucagon (German et al., 2010; Wang et al., 2010). In
response to physiological doses of leptin, blood glucose levels
are only slightly lowered, despite similar decreases in glucagon
levels and corticosterone levels (German et al., 2010). They did
find that leptin replacement prevented insulin resistance at the
level of the liver, independently of its effects on food intake and
body weight, via reduction of hepatic triglyceride content,
decreases in hepatic expression of gluconeogenic genes (i.e.,
glucose-6-phosphatase and phosphoenolpyruvate kinase),
and improvement of insulin signaling at the level of PI3K; these
effects were not shown in the skeletal muscle or adipose tissue.
Intracerebroventricular leptin treatment has been shown to
normalize glucose levels by suppressing hepatic glucose pro-
duction, but also by increasing insulin-independent glucose up-
take in peripheral tissues, including the skeletal muscle, heart,
and brown adipose tissue, via the sympathetic nervous system
activation (German et al., 2011).
In ‘‘experiments of nature’’ studies, two patients with concom-
itant type 1 autoimmune diabetes and acquired generalized
lipodystrophy demonstrated severe insulinopenia and extreme
insulin resistance, requiring higher insulin dosing than expected
based on weight (Park et al., 2008). After the initiation of
leptin treatment, insulin requirements decreased dramatically.
In contrast, although leptin treatment has resulted in dramatic
improvement in insulin resistance in patients with congenital lep-
tin deficiency and lipodystrophy, leptin treatment has been inef-
fective in improving glycemic control and body weight in patients
with type 2 diabetes mellitus, likely due to leptin resistance
(Moon et al., 2011). No studies have been performed in patients
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see whether leptin can serve as an adjunct to insulin therapy.
Lipid Metabolism
Leptin regulates lipid metabolism in conjunction with insulin, but
they do so in opposing ways. While insulin acutely stimulates
lipogenesis, leptin stimulates fatty-acid oxidation via AMP-acti-
vated protein kinase pathway to prevent the accumulation of
lipids in nonadipose tissue and the resultant lipotoxicity (Mino-
koshi et al., 2002). Leptin replacement in patients with congenital
leptin deficiency has been shown to decrease insulin-mediated
stimulation of lipogenesis (Paz-Filho et al., 2008a). These
patients havemild dyslipidemia and particularly low HDL choles-
terol levels, and leptin replacement has been shown to improve
their triglyceride and HDL and LDL cholesterol levels (Farooqi
et al., 2002; Licinio et al., 2004). Additionally, uncontrolled,
open-label studies in humans with congenital and acquired
lipodystrophies and complete leptin deficiency have shown
that leptin treatment results in significant improvement in hepatic
steatosis and intramyocellular lipid content (Musso et al., 2005;
Petersen et al., 2002).
Similar but less-robust effects are seen in patients with
HIV-associated lipodystrophy, as these patients do not have
an absolute leptin deficiency relative to those with congenital
lipodystrophy. In a 6-month open-label study of eight men with
HIV-associated lipodystrophy, leptin treatment decreased lipol-
ysis and LDL and non-HDL cholesterol and increased HDL
cholesterol (Mulligan et al., 2009). In our randomized, placebo-
controlled, crossover study in seven patients with HIV-associ-
ated lipodystrophy, 2-month metreleptin treatment improved
truncal obesity and insulin sensitivity, and its positive effects
on HDL, LDL, and triglycerides were mediated through changes
changes in intrabdominal fat (Lee et al., 2006). Results similar to
ours were reported in another recent 4-month, randomized,
placebo-controlled trial, which found a modest decrease in
non-HDL levels, although no changes in triglyceride or HDL
levels were observed (Sekhar et al., 2012). The varying efficacies
of leptin in these metabolic abnormalities need to be studied
further to determine which subset of patients with HIV-associ-
ated lipodystrophy would benefit the most, which may be prim-
itively related to the severity of leptin deficiency.
The Role of Leptin in Bone Metabolism
Leptin affects bone metabolism differently via central and
peripheral means. Centrally, mouse studies suggest that leptin
induces cortical bone formation via b1 sympathetic activation
and/or the GH-IGF-1 axis, but also induces trabecular bone
remodeling with loss in volume via b2 sympathetic activation
(Hamrick and Ferrari, 2008). Data from mouse studies also indi-
cate that leptin may mediate bone metabolism either positively
or negatively by regulating the expression of several neuropep-
tides in the hypothalamus, including NPY (Baldock et al., 2006)
and neuromedin U (Sato et al., 2007).
Peripherally, leptin interacts with bone marrow stromal cells
and osteoblasts to increase overall bone mass. Leptin increases
expression of osteogenic genes in stromal cells, directing them
down the osteogenic instead of adipogenic pathway (Bartell
et al., 2011). Leptin also stimulates stromal cells to increase
osteoprotegerin expression and decrease RANK ligand, result-
ing in decreased osteoclastogenesis (Holloway et al., 2002). Inin vitro and in vivo mouse studies, leptin has also been shown
to increase osteoblast proliferation, de novo collagen synthesis,
and mineralization (Gordeladze et al., 2002).
Although no correlation between bone mineral density and
leptin has been found in normal weight children or adolescents
or healthy postmenopausal women (Roemmich et al., 2003), in-
terventional studies suggest that leptin may be more important
for bone health in patients with leptin deficiency. Despite the
fact that patients with congenital leptin deficiency have age-
and gender-appropriate bone mineral content and bone mineral
density, unlike ob/ob mice, which have 25% lower bone mass
(Hamrick et al., 2005), leptin treatment increases their skeletal
maturation (Farooqi et al., 2002). In women with hypothalamic
amenorrhea, we reported significant changes in markers of
bone turnover, suggestive of bone formation, compared to
placebo-treated subjects (Chou et al., 2011; Welt et al., 2004)
and, over the course of 2 years of treatment, increases in lumbar
spinal bone mineral density and bone mineral content compared
to baseline (Sienkiewicz et al., 2011). However, it remains to be
determined whether this increase in bone-formation markers
and bone mineral density and content is a direct effect of leptin
and/or mediated by restoration of estradiol and/or IGF-1 and
cortisol levels.
An important issue that remains to be elucidated is whether
hypoleptinemia increases fracture risk, which is the hard
endpoint of metabolic bone disease. Only recently was impaired
fracture healing (delay in callus maturation and increase in total
callus volume) shown radiographically and histologically in ob/
ob compared with control mice subjected to open stabilized
middiaphyseal femur fractures; local leptin application reversed
the delay in healing in ob/obmice (Khan et al., 2013). Given that
currently only cross-sectional studies have evaluated leptin
levels in patients with low-energy fractures and have provided
controversial results, it remains to be elucidated whether leptin
administration in patients with lipodystrophy and hypoleptinemia
might have an effect on fracture prevention or therapy.
The Role of Leptin in Immune Function
Leptin has also been proposed to link energy metabolism with
the inflammatory and immune responses, particularly the
CD4+ T-helper-1 response (Carbone et al., 2012). In ex vivo
studies, leptin has been shown to promote proliferation and
interleukin-2 (IL-2) secretion by naive T cells, enhance phago-
cytic activity in macrophages, enhance proliferation and
cytotoxicity of natural killer cells, stimulate chemotaxis in poly-
morphonuclear cells, and promote production of proinflamma-
tory cytokines, such as tumor necrosis factor-a (TNF-a), IL-6,
and IL-12 (Carbone et al., 2012). In vitro, we have shown that lep-
tin promotes lymphocyte survival by suppressing Fas-mediated
apoptosis (Papathanassoglou et al., 2006). Additionally, an
in vivo study showed that leptin administration improved the
immune dysfunction of ob/ob mice and protected against
immune dysfunction in acutely starved wild-type mice (Howard
et al., 1999).
Compared to the general population, individuals with congen-
ital leptin deficiency have a higher incidence of infection. One
leptin-deficient patient was reported to have decreased prolifer-
ation and function of CD4+ T cells at baseline, which normalized
after exogenous leptin replacement (Farooqi et al., 2002).Cell Metabolism 18, July 2, 2013 ª2013 Elsevier Inc. 37
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evident immune dysfunction and exhibit normal absolute num-
ber and percentage of T cells, leptin treatment has been shown
to increase the number of T cells, both CD4+ and CD8+, and in-
crease TNF-a secretion from peripheral bloodmononuclear cells
in vitro to normal levels in response to lipopolysaccharide and
lipopolysaccharide plus IFN-g treatment, suggesting that the
response is mediated through the Toll-like receptor pathway
(Oral et al., 2006). Overall, these immunomodulatory effects in
lipodystrophic patients were modest (Oral et al., 2006). Our
group has studied the effect of leptin administration on the
immune system in women with hypothalamic amenorrhea and
relative leptin deficiency and found that it leads to greater activa-
tion of the TNF-a system (Chan et al., 2005) and to the restoration
of CD4+T cell counts and their in vitro proliferative responses via
specific transcriptional changes (Matarese et al., 2013).
However, leptin’s role in immune function seems to be permis-
sive, as leptin replacement had no major effect on fasting-
induced changes on most immunophenotypes in normal-weight
women with fasting-induced hypoleptinemia (Chan et al., 2006).
Our group also showed that leptin administration to raise
circulating levels in lean and obese men resulted in no signifi-
cant increase in cytokines and inflammatory markers (Chan
et al., 2005). As such, our data to date do not suggest a role
for leptin in the pathogenesis of the obesity-related proinflamma-
tory state.
Emerging Clinical Applications
Since its discovery in 1994 as an adipocyte-secreted hormone,
leptin has been implicated in various aspects of energy homeo-
stasis and metabolism through numerous regulatory pathways
involving several organs. Recent research further implicates
leptin as a key player in yet other diverse functions, such as
the regulation of the immune system or bone metabolism;
however, this may be an early speculation, even these leptin
actions may be a function of energy status/availability. Never-
theless, despite significant progress in elucidating the patho-
physiological role of leptin, many issues still remain to be
explored.
Its role at the intersection of neuroendocrinology and meta-
bolism renders leptin an appealing therapeutic target for the
management of disorders related to energy homeostasis. Leptin
treatment has been shown to correct the neuroendocrine and
metabolic abnormalities seen in patients with leptin deficiency
and lipodystrophy. Currently, leptin is available to the rare
patient with congenital leptin deficiency through a compas-
sionate-use program at Amylin Pharmaceuticals (San Diego), a
company recently acquired by Bristol-Myers Squibb. These
hypoleptinemic patients—who have severe neuroendocrine
abnormalities and develop extreme obesity very early in life—
exhibit decreased appetite, diminished food intake, marked
decreases in fat mass, and resolution of their neuroendocrine
irregularities, including the inability to progress through puberty,
with leptin treatment (Ozata et al., 1999). Leptin’s utility in this
setting is highly apparent.
Amylin Pharmaceuticals also has a FDA-approved expanded
access program for the use of leptin in patients with congenital
lipodystrophy. Though congenital lipodystrophy is rare, acquired
lipodystrophy as a result of highly active antiretroviral therapy38 Cell Metabolism 18, July 2, 2013 ª2013 Elsevier Inc.(HAART) for the treatment of HIV/AIDS has become more
common. Individuals with HIV-associated lipodystrophy, who
comprise a much larger and growing population, are leptin defi-
cient and, upon treatment with recombinant human leptin,
exhibit improvements in insulin resistance and hyperlipidemia
comparable to those seen with other treatments, including met-
formin and thiazolidinediones (Lee et al., 2006; Mulligan et al.,
2009). Hopefully, therapeutic use of leptin will expand to patients
with HIV-associated lipodystrophy once further clinical trials
establish treatment protocols (Brennan et al., 2009).
In addition to treatment for patients with congenital and
other acquired leptin deficiency, recombinant human leptin is
emerging as a potential treatment for conditions associated
with relative hypoleptinemia, such as lipodystrophy and hypo-
thalamic amenorrhea. We have found that in women with
hypothalamic amenorrhea and in individuals with acquired
lipodystrophy leptin administration in replacement doses may
correct the metabolic abnormalities observed in these leptin-
deficient states (Chou et al., 2011; Oral et al., 2006; Sienkiewicz
et al., 2011; Welt et al., 2004). Leptin replacement therapy may
also have numerous other observed physiological benefits,
including improved immune status in patients with generalized
and severe lipodystrophy, normalized menstrual patterns in
young women with lipodystrophy and polycystic ovary syn-
drome (Mittendorfer et al., 2011), and improved hypothalamic
neuroendocrine axes in women with HA (Kusakabe et al.,
2009). Large phase III clinical trials are needed to confirm these
findings and to determine the clinical efficacy of leptin replace-
ment therapy in these populations.
Leptin sensitivity remains an issue when considering the
potential for leptin treatment in subjects with hyperleptinemia
and energy excess, such as obesity. Clinical trials exploring lep-
tin monotherapy for weight loss have subsided due to under-
whelming results (Heymsfield et al., 1999; Moon et al., 2011).
The amount of weight loss was not markedly more than that
observed as a result of behavioral interventions or pharmacolog-
ical treatments using orlistat, sibutramine, or a combination of
phentermine and topiramate (up to 5–10 kg) (Leblanc et al.,
2011). Leptin resistance is still obviously a potent and recalci-
trant factor, the underlying molecular mechanisms of which are
now being actively explored (Moon et al., 2011).
Given that leptinmonotherapy does not seem to be efficacious
in promoting weight management among leptin-resistant obese
individuals, leptin combination therapy for obesity may be a
promising treatment for garden-variety obesity, which, aside
from costly and risky bariatric surgery, is a chronic disease
with few successful long-term therapeutical options. Newer trials
have focused on the weight loss effects of leptin coadministra-
tion with possible leptin sensitizers like amylin, a hormone
secreted by the pancreas that also is involved in the regulation
of energy homeostasis (Ravussin et al., 2009; Roth et al.,
2008). In a study conducted by Amylin Pharmaceuticals, over-
weight and obese subjects lost significantly more weight on a
combination of leptin and pramlintide, an amylin analog,
compared to either agent alone, though in an additive, and not
synergistic, fashion, suggesting that amylin does not improve
the sensitivity to leptin (Ravussin et al., 2009). Roth et al. found
similarly additive results in humans, but did find a synergistic
weight loss response in diet-induced obese rats, which was
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the ventromedial hypothalamus and hindbrain area postrema
(Roth et al., 2008).
Other combinations of leptin and leptin-sensitizers have been
studied in rodents, and although some are promising, their
effects also may not be well translated in humans. In addition
to augmenting leptin’s anorectic and weight-loss-promoting
effects, metformin seems to restore leptin sensitivity in diet-
induced obese rats (Kim et al., 2006). In these rats, leptin
monotherapy did not increase POMC expression, while leptin
and metformin combination therapy did. Additionally, when
used in combination with metformin a lower dose of leptin
was required to decrease the hypothalamic pAMPK level.
These data collectively indicate that leptin plus metformin com-
bination therapy may be particularly useful in promoting
anorexigenic and suppressing orexigenic pathways within the
CNS (Anderson et al., 2008; Kim et al., 2006). As further evi-
dence, additional studies performed in rats have shown that
combined leptin therapy with previously approved medications
for weight loss, including sibutramine or rimonabant, a canna-
binoid CB1 receptor antagonist, results in greater decreases
in food intake and weight loss compared to monotherapy
(Boustany-Kari et al., 2011). Combined leptin and rimonabant
treatment was also found to synergistically increase and
decrease neuronal firing in the ventromedial hypothalamus
and ARC, respectively, signifying a highly potent antiobesity
effect (Boustany-Kari et al., 2011). Additionally, in diet-induced
obese mice, combination therapy of leptin analog with either
exendin-4, a long-acting glucagon-like peptide 1 receptor
agonist, or FGF21, another important modulator of glucose
metabolism and energy expenditure, additively enhanced
weight loss (Mu¨ller et al., 2012). However, this benefit did not
emerge until after an initial weight loss of 30%, which seemed
to be the threshold for the pharmacologic restoration of leptin
sensitivity in these mice. Larger trials in this capacity are
needed to determine the utility of leptin in the context of weight
loss management and to determine whether a threshold
amount of initial weight loss is necessary to reinstate leptin
sensitivity in obese or overweight subjects. Finally, large ran-
domized leptin administration studies are needed to obtain
accurate information on potential adverse effects and long-
term outcomes of combination therapy.
The notion of a threshold in terms of BMI levels or leptin
levels needed for the restoration of leptin sensitivity has
prompted focus on leptin’s role in weight loss maintenance.
Increased hunger and the danger of increased food intake
are consistently problematic throughout weight loss mainte-
nance (Kissileff et al., 2012; Rosenbaum et al., 2005). However,
these may arise as a direct result of the decreases in circulating
leptin levels that occur due to weight loss and energy depriva-
tion. This is a very acute area of research which is expected to
result in major therapeutic advances in the not so distance
future.
Although leptin administration has proven helpful in the
management of lipodystrophy and other acquired hypoleptine-
mic states, the overall efficacy of leptin therapy in the treatment
of these states remains unclear, since large, well-controlled,
randomized studies have yet to show whether all patients with
lipodystrophy or only those who are extremely leptin deficientwould benefit from leptin therapy. Moreover, a growing body of
evidence from preclinical, in vitro, and animal studies indicates
that leptin administration in such states may be associated
with possible side-effects, and this needs to also be studied in
the context of large future trials.
Notably, any potential adverse effects associated with leptin
administration may differ among hypoleptinemic versus hyper-
leptinemic states. Leptin administration in hyperleptinemic
states has also been hypothesized to contribute to a host of
side effects including hypertension, thrombosis/angiogenesis,
and increased inflammation (Ravussin et al., 2009), although
we have failed to observe these effects in our clinical studies
(Aronis et al., 2011; Chan and Mantzoros, 2005; Chan et al.,
2007; Moon et al., 2011).
Investigators have also examined concerns for the carcino-
genic potential of leptin administration in patients with garden-
variety obesity. In vitro studies suggest that leptin may prompt
neoplasia through two mehcanisms: (1) activation of receptor-
mediated growth and survival signaling pathways, such as
JAK2/STAT3, PI3k/Akt, and MAPK/extracellular-signal-regu-
lated kinase (ERK) (Gibson et al., 2004) and (2) increasing inflam-
matory and cytokine response (Hwang et al., 2008). Notably,
most in vitro studies that have observed carcinogenic effects
have used very high leptin levels, whereas in vivo clinical studies
using physiologic or pharmacologic doses of leptin have not
revealed any consistent associations between leptin levels and
cancer risk. Larger prospective, mechanistic, and longitudinal
studies are urgently needed to thoroughly evaluate this risk
before leptin can be implemented as a treatment approach in
patients with diabetes or obesity.
In conclusion, future large-scale clinical and epidemiological
trials are required to assess the full spectrum of potential
adverse effects associated with leptin replacement therapy
and to determine its efficacy and safety in addition to the best
safety monitoring practices. Given the lack of efficacy of leptin
in garden-variety obesity and/or diabetes, trials are also needed
to determine whether the discovery and concomitant use of
other leptin sensitizers would be useful in the treatment of
obesity or in the promotion of weight maintenance. Similarly,
large-scale clinical trials are needed to determine not only (1)
the appropriate upper and lower doses of leptin needed to
optimize metabolic response and safely overcome leptin resis-
tance, but also (2) the diagnostic criteria for hypo- and hyperlep-
tinemia in order to provide the basis for inclusion criteria in
future investigative trials, given that the definition of relative
deficiency or excess of leptin levels (i.e., specific leptin cutoff
points) seem to be critical to maximizing the benefits and mini-
mizing the drawbacks of leptin use. Hence, although great prog-
ress has been made in terms of understanding leptin’s role in
(patho-)physiology, several fundamental questions still remain
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